Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Radioimmunotherapy (RIT) with 90 yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL)

Barbara Botto, MD, Chiara Ciochetto, Marilena Bellò, Roberto Passera, Giulia Benevolo, MD, Carola Boccomini, MD, Annalisa Chiappella, Roberto Freilone, Francesca Giunta, Maura Nicolosi, Erika Orlandi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, MD, Anna Tonso, Gianni Bisi, Umberto Vitolo, MD

Blood (2011) 118 (21): 3107.

https://doi.org/10.1182/blood.V118.21.3107.3107

Published: 2011

Journal Articles

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Blood (2011) 118 (21): 1606.

https://doi.org/10.1182/blood.V118.21.1606.1606

Published: 2011

Journal Articles

COMPARISON Among Citology, Histology, and FLOW Cytometry IN Evaluating Blast VALUES IN Myelodysplatic Syndromes (MDS). Survey FROM the Italian “PIEMONTE MDS REGISTRY”

Blood (2010) 116 (21): 4028.

https://doi.org/10.1182/blood.V116.21.4028.4028

Published: 2010

Journal Articles

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Blood (2009) 114 (22): 2316.

https://doi.org/10.1182/blood.V114.22.2316.2316

Published: 2009

Journal Articles

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Blood (2008) 112 (11): 2680.

https://doi.org/10.1182/blood.V112.11.2680.2680

Published: 2008

Journal Articles

Hematological Improvement in AML/RAEB Elderly Patients Treated with Valproic Acid and Low-Dose ARA-C

Maria Teresa Corsetti, MD, Flavia Salvi, MD, Sonia Perticone, Bernardino Allione, MD, Anna Baraldi, MD, Alessandro Bellora, MD, Lorella De Paoli, MD, Simona Gatto, MD, Daniela Pietrasanta, MD, Valeria Primon, MD, Massimo Pini, MD, Anna Tonso, MD, Marco Musi, MD, Giorgio Ciravegna, MD, Francesco Zallio, MD, Alessandro Levis, MD

Blood (2008) 112 (11): 2971.

https://doi.org/10.1182/blood.V112.11.2971.2971

Published: 2008

Journal Articles

Improvement of Remission Duration with Low-Dose Post-Remissional Gemtuzumab Ozogamicin (GO) in Elderly Patients with Acute Myeloid Leukemia

Filippo Marmont, Ernesta Audisio, Stefano D’Ardia, Flavia Salvi, Anna Tonso, Dario Ferrero, Alessandro Levis, Umberto Vitolo, MD

Blood (2008) 112 (11): 4024.

https://doi.org/10.1182/blood.V112.11.4024.4024

Published: 2008

Journal Articles

Activated B-Cell (ABC) Profile Does Not Have An Inferior Outcome Compared to Germinal Center B-Cell (GCB) Profile Determined by Immunohistochemistry Tissue Microarray in Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and Dose- Dense and High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT).

Blood (2008) 112 (11): 1139.

https://doi.org/10.1182/blood.V112.11.1139.1139

Published: 2008

Journal Articles

Radioimmunotherapy (RIT) with 90 y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens

Barbara Botto, Marilena Bellò, Annalisa Chiappella, Roberto Passera, Giulia Benevolo, Carola Boccomini, Maria Giuseppina Cabras, Claudia Castellino, Giuseppe Fioritoni, Chiara Frairia, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Umberto Ricardi, Giovanni Bisi, Umberto Vitolo

Blood (2008) 112 (11): 5014.

https://doi.org/10.1182/blood.V112.11.5014.5014

Published: 2008

Journal Articles

Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).

Annalisa Chiappella, Giuseppe Rossi, Maria Giuseppina Cabras, Anna Marina Liberati, Giovannino Ciccone, Flavia Salvi, Emanuele Angelucci, Barbara Botto, Antonella Darbesio, Roberto Freilone, Lorella Orsucci, Vincenzo Pavone, Enrico Maria Pogliani, Umberto Ricardi, Delia Rota-Scalabrini, Anna Tonso, Alessandra Tucci, Eugenio Gallo, Umberto Vitolo

Blood (2007) 110 (11): 1899.

https://doi.org/10.1182/blood.V110.11.1899.1899

Published: 2007

Journal Articles

Radioimmunotherapy (RIT) with 90 Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.

Barbara Botto, Marilena Bellò, Giulia Benevolo, Maria Giuseppina Cabras, Claudia Castellino, Annalisa Chiappella, Giuseppe Fioritoni, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Giovanni Bisi, Umberto Vitolo, Eugenio Gallo

Blood (2007) 110 (11): 4478.

https://doi.org/10.1182/blood.V110.11.4478.4478

Published: 2007

Journal Articles

Prognostic Role of Transfusion Requirement and Validation of the IPSS Prognostic System in Myelodisplastic Syndromes.

Blood (2006) 108 (11): 2622.

https://doi.org/10.1182/blood.V108.11.2622.2622

Published: 2006

Journal Articles

Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III–IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.

Blood (2006) 108 (11): 329.

https://doi.org/10.1182/blood.V108.11.329.329

Published: 2006

Journal Articles

A Short Weekly Chemotherapy Regimen (ACOP-B) Followed by Involved Field Radiotherapy in Limited Stage Aggressive Non-Hodgkin Lymphoma. Multicentric Analyses of Toxicity, Efficacy and Long Term Follow up.

Maria Giuseppina Cabras, MD, Roberto Freilone, MD, Angela Mamusa, MD, Paolo Dessalvi, MD, Anna Tonso, MD, Lorella Orsucci, MD, Umberto Vitolo, MD, Emanuele Angelucci, MD

Blood (2006) 108 (11): 2435.

https://doi.org/10.1182/blood.V108.11.2435.2435

Published: 2006

Journal Articles

Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes.

Blood (2005) 106 (11): 2543.

https://doi.org/10.1182/blood.V106.11.2543.2543

Published: 2005

Journal Articles

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Blood (2005) 106 (11): 676.

https://doi.org/10.1182/blood.V106.11.676.676

Published: 2005

Journal Articles

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Blood (2004) 104 (11): 1320.

https://doi.org/10.1182/blood.V104.11.1320.1320

Published: 2004

Journal Articles

Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study.

Umberto Vitolo, Anna Marina Liberati, Maria Giuseppina Cabras, Giuseppe Rossi, Alessandro Levis, Enzo Pavone, Emanuele Angelucci, Carola Boccomini, Lisa Bonello, Barbara Botto, Annalisa Chiappella, Francesco Di Vito, Isabella Palumbo, Enrico Pogliani, Delia Rota-Scalabrini, Flavia Salvi, Anna Tonso, Alessandra Tucci, Eugenio Gallo

Blood (2004) 104 (11): 1321.

https://doi.org/10.1182/blood.V104.11.1321.1321

Published: 2004

Journal Articles

Lack of SH3 domain does not imply a more severe clinical course in Ph + chronic myeloid leukemia patients

Mario Tiribelli, Anna Tonso, Dario Ferrero, Adele Parziale, Giovanna Rege Cambrin, Patrizia Scaravaglio, Daniela Cilloni, Enrico Gottardi, Giuseppe Saglio

Blood (2000) 95 (12): 4019–4020.

https://doi.org/10.1182/blood.V95.12.4019

Published: 2000

NARROW

Radioimmunotherapy (RIT) with 90 yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL)

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

COMPARISON Among Citology, Histology, and FLOW Cytometry IN Evaluating Blast VALUES IN Myelodysplatic Syndromes (MDS). Survey FROM the Italian “PIEMONTE MDS REGISTRY”

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Hematological Improvement in AML/RAEB Elderly Patients Treated with Valproic Acid and Low-Dose ARA-C

Improvement of Remission Duration with Low-Dose Post-Remissional Gemtuzumab Ozogamicin (GO) in Elderly Patients with Acute Myeloid Leukemia

Radioimmunotherapy (RIT) with 90 y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens

Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).

Radioimmunotherapy (RIT) with 90 Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.

Prognostic Role of Transfusion Requirement and Validation of the IPSS Prognostic System in Myelodisplastic Syndromes.

Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III–IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.

A Short Weekly Chemotherapy Regimen (ACOP-B) Followed by Involved Field Radiotherapy in Limited Stage Aggressive Non-Hodgkin Lymphoma. Multicentric Analyses of Toxicity, Efficacy and Long Term Follow up.

Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes.

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study.

Lack of SH3 domain does not imply a more severe clinical course in Ph + chronic myeloid leukemia patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only